Osiris Volume Through the Roof, on Bad News (OSIR)

Posted in General 
March 27th, 2009

Osiris Therapeutics, Inc. (NASDAQ: OSIR) is seeing its stock battered this morning on exponential volume.   The company announced that it was ending enrollment at 210 patients in its Phase III trial evaluating its Prochymal for Crohn’s disease.  Shares are down 22% at $14.25 and we are over 950 shares as of only 9:57 AM EST. This stock has also traded as low as just under $13.00 in earlier trading.  Its average daily volume is only 190,000 shares, and the 52-week range is $10.80 to $21.65.

FULL STORY at 24/7 Wall St.

MARCH 27, 2009

Comments are closed